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Purpose: To evaluate the effectiveness of additional knee joint stabili-
zation therapy, prior tomuscle strengthening and functional exercises in
patients with knee osteoarthritis (OA) and instability of the knee joint.
Methods: Single-blind, randomized, controlled trial (NTR1475)
involving 159 knee OA patients with self-reported or biomechanically
assessed knee instability. Experimental treatment was a 12-week
exercise program initially focusing on knee stabilization, prior tomuscle
strength and performance of functional activities. Control treatment
was a 12-week exercise program consisting of muscle strengthening
and functional exercises only. Primary outcome measure was self-re-
ported activity limitations (WOMAC, subscale physical function),
assessed at baseline, 6-week, 12-week and 38-week follow-up.
Secondary outcome measures included pain, observed activity limita-
tions and knee instability.
Results: Both treatment groups demonstrated large (w30-40%) and
clinically relevant reductions in activity limitations, pain and knee
instability, which were sustained six months post-treatment. Knee joint
stabilization training did not show additional effect compared to the
control treatment on primary outcome measure WOMAC, physical
function (B (95% CI) ¼ -0.01 (-2.58-2.57)) (see Figure 1) or secondary
outcome measures, except for higher global perceived effect in the
experimental group (p¼.04). Subgroup analyses revealed an interaction
(p¼.02) between baseline upper leg muscles strength and treatment
effect on WOMAC, physical function (see Figure 2).
Conclusions: Both exercise programswere effective in reducing activity
limitations and pain and restoring knee stability. In the total group,
initial knee joint stabilization training was not found to be effective in
knee OA patients with instability of the knee, suggesting a dominant
role of muscle function in knee joint stabilization. Results from
subgroup analyses were indicative for an effect of additional knee joint
stabilization training in persons with already high upper leg muscle
strength.Ă
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Purpose: Objective was to evaluate TNF blockers in patients with
painful hand OA refractory to analgesics and NSAIDs.
Methods: This is a phase 3 randomized superiority, double-blind,
placebo controlled, 26 weeks, multicenter trial, using TNF blocker
adalimumab (2 sub cutaneous injections at week 0 and week 2).
Patients meeting the ACR criteria for hand OA with pain above 40 mm,
involving at least 3 painful interphalangeal joints, who did not respond
to analgesics and NSAIDs, were recruited. The primary endpoint was the
number of responders (more than 50% of improvement) at 6 weeks.
Secondary outcomes were: number of painful joints and of swollen
joints, morning stiffness, patient global assessments, functional index
for hand OA. Consumption of analgesics was recorded (acetaminophen
up to 3g/D as a rescue medication). Serum markers (COMP, PIIANP, HA,
usCRP, cytokines level of TNF a, IL-6, IL-1) and urine level of CTX-II
(corrected by creatinine) were measured at W0 and W6.
Results: On the 99 patients selected, 85 were randomized (42 placebo ,
41 adalimumab). 78 patients with at least one injection were analyzed
(37 placebo and 41 adalimumab) (mITT). Mean (SD) age was 62.5 (6.9),
85 % of women, mean (SD) level of pain was 65.4 (12.9) mm; mean (SD)
number of painful IP joints: 11 (6). At W6, there was no difference
between groups on the main outcome measure: 35.1% in the adalimu-
mab group versus 27.3% in the placebo group (RR: 1.12 (95% CI: 0.82-
1.54; p¼0.48) corresponding to an intergroup difference of: -2.5 mm
(95% CI, -14.0 to 9.0), p: 0.67. No statistically signiﬁcant differences were
found for any of the secondary outcomes. Analgesics use was similar
between groups. There were no safety concerns. There was none vari-
ations of any biological markers between the 2 groups.
Conclusions: In a group of patients with refractory hand OA, TNFa
blockers (adalimumab, 2 sc injections) failed to demonstrate any clinical
improvement.
Trial registration clinicaltrials.gov Identiﬁer: NCT00597623272
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Purpose: To identify if a tailored rehabilitation programme is more
effective than standard practice at improving function in patients
